中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Issue 11
Nov.  2017
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2017  >  33(11): 2062-2071

An interpretation of World Gastroenterology Organisation global guidelines: diagnosis, management, and prevention of hepatitis C (2017 update)

DOI: 10.3969/j.issn.1001-5256.2017.11.004

  • Department of Infectious Diseases & The Center of Diagnosis and Treatment for Infectious Diseases of PLA, Tangdu Hospital, Forth Military Medical University

  • Published Date: 2017-11-20
    Abstract
    • FullText(HTML)
  • loading
    • References(7)
  • [1]World Gastroenterology Organisation.World Gastroenterology Organisation global guidelines:diagnosis, management, and prevention of hepatitis C (2017 update) [EB/OL].World Gastroenterology Organisation, 2017.
    [2]European Association for Study of Liver.EASL recommendations on treatment of hepatitis C 2016[J].J Hepatol, 2017, 66 (1) :153-194.
    [3]AASLD/IDSA HCV guidance panel.Hepatitis C guidance:AASLD-ID-SA recommendations for testing, managing, and treating adults infected with hepatitis C virus[J].Hepatology, 2015, 62 (3) :932-954.
    [4]OMATA M, KANDA T, WEI L, et al.APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing[J].Hepatol Int, 2016, 10 (5) :681-701.
    [5]WHO Guidelines Approved by the Guidelines Review Committee.Guidelines for the screening care and treatment of persons with chronic hepatitis C infection:updated version[Z].Geneva:World Health Organization, 2016.
    [6]WANG YY, NIE QH.Study of direct-acting antiviral (DAA) and their treatment for chronic hepatitis C[J].Chin Hepatol, 2016, 21 (2) :140-142. (in Chinese) 王媛媛, 聂青和.直接抗病毒药物研究及其治疗慢性丙型肝炎现状[J].肝脏, 2016, 21 (2) :140-142.
    [7]ZHAO XT, NIE QH.Adverse effects, drug interactions, and safety of direct-acting antiviral agents in treatment of hepatitis C[J].JClin Hepatol, 2017, 33 (6) :1067-1074. (in Chinese) 赵西太, 聂青和.直接抗病毒药物治疗丙型肝炎的毒副作用、药物相互作用及安全性[J].临床肝胆病杂志, 2017, 33 (6) :1067-1074.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (361) PDF downloads(324) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return